Message #77 From:
NewsBot Date: January 3, 2007 04:30:00 AM
ALNY News Alnylam to Webcast Presentation at the 25th Annual JPMorgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi
therapeutics company, today announced that management will present a
company overview at the 25th Annual JPMorgan
Healthcare Conference on January 9, 2007 at 1:30 p.m. PT (4:30 p.m. ET)
at the Westin St. Francis Hotel in San Francisco.
A live audio webcast of this presentation will be available on the “Investors”
section of the company’s website, www.alnylam.com.
A replay of the presentation will be posted on the Alnylam website
approximately three hours after the event, and will be archived for 14
days.
About Alnylam
Alnylam is a biopharmaceutical company developing novel therapeutics
based on RNA interference, or RNAi. The company is applying its
therapeutic expertise in RNAi to address significant medical needs, many
of which cannot effectively be addressed with small molecules or
antibodies, the current major classes of drugs. Alnylam is building a
pipeline of RNAi therapeutics; its lead program is in Phase I human
clinical trials for the treatment of respiratory syncytial virus (RSV)
infection, which is the leading cause of hospitalization in infants in
the U.S. The company’s leadership position in
fundamental patents, technology, and know-how relating to RNAi has
enabled it to form major alliances with leading companies including
Merck, Medtronic, Novartis, and Biogen Idec. The company, founded in
2002, maintains global headquarters in Cambridge, Massachusetts, and has
an additional operating unit in Kulmbach, Germany. For more information,
visit www.alnylam.com.
